So far, only one aptamer-based drug, Macugen (pegaptanib sodium, Pfizer/Eyetech), an RNA aptamer specific against vascular endothelial growth factor (VEGF), was approved by the US Food and Drug Administration (FDA) in 2004 for treating wet age-related macular degeneration [27]. Here, VEGFA is linked to wet macular degeneration.